Granules India Reports Strong FY26 Performance

Granules India has announced its financial results for the fiscal year ended March 31, 2026, reporting significant year-over-year growth.

Full-Year Financial Performance

For the full year FY26, the company posted revenue of ₹53,656 crore, a 20% increase. Profit After Tax (PAT) rose 19% to ₹5,950 crore. Granules India also achieved a record Gross Margin of 65.0% and reported EBITDA of ₹11,851 crore, up 25% year-over-year. Fourth-quarter (Q4 FY26) performance mirrored this strength, with revenue increasing 23% to ₹14,706 crore and PAT surging 33% to ₹2,016 crore.

Strategic Shift Drives Margin Growth

This strong financial performance highlights Granules India's strategic shift toward a value-driven business model. The company has increased the proportion of 'Complex Generics' (Complex Gx) products within its Finished Dosages (FD) segment, which now accounts for 43% of FD revenue, up from 31% previously. This move, supported by investments in R&D and capacity, is driving margin expansion due to the higher-value nature and entry barriers of these complex products.

Strategic Evolution and Regulatory Context

Granules India is transforming from a pure API supplier into an integrated pharmaceutical player. This strategy is supported by considerable capital expenditure and a ₹1,762.50 crore capital raise completed in February 2026. The company enhanced its capabilities in peptide development and the Contract Development and Manufacturing Organization (CDMO) space through the acquisition of Senn Chemicals AG and its subsidiary Ascelis Peptides, diversifying revenue streams and profitability. However, the company has navigated regulatory challenges, including a US FDA warning letter issued in February 2025 for its Gagillapur facility concerning Good Manufacturing Practice (GMP) violations. More recently, in April 2026, its US subsidiary's Chantilly facility underwent an audit, which noted procedural observations but no data integrity issues.

Outlook and Investor Focus

Investors can expect Granules India to continue prioritizing higher-margin, complex products, which could drive sustained earnings growth. The rising share of Complex Gx and Finished Dosages is projected to enhance overall profitability and Return on Capital Employed (ROCE). Ongoing investment in research and development (R&D) and capital expenditure (CAPEX) underscores the company's commitment to future growth and expanding its production capacity.

Risks to Watch

Key risks for Granules India include general economic conditions, regulatory changes, competition, and currency fluctuations. The ongoing remediation required by the US FDA warning letter for the Gagillapur facility remains critical, as it could affect future product approvals. Additionally, a patent infringement lawsuit filed by Jazz Pharmaceuticals in August 2025 regarding a generic version of Xywav poses a legal challenge.

Peer Comparison

Granules India competes with major Indian pharmaceutical companies such as Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., and Lupin Ltd. While these peers also focus on expanding formulation portfolios and global presence, Granules' strategic emphasis on complex generics and CDMO expansion provides a distinct growth path.

Key Investment Metric

Capital expenditure (CAPEX) for the period FY22-FY26 totaled ₹23,107 crore.

What to Track Next

Investors will closely monitor the progress of US FDA remediation efforts at the Gagillapur facility and related product approval updates. The successful integration and growth contribution from the Senn Chemicals acquisition and the company's CDMO business will be crucial. Further developments in the patent litigation with Jazz Pharmaceuticals will also be watched. The performance of the Complex Gx segment and its impact on overall margins remains a key indicator for future profitability.